Using bradykinin-potentiating peptide structures to develop new antihypertensive drugs

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Angiotensin I-converting enzyme (ACE) is crucial for blood pressure regulation and a key target in cardiovascular and renal disease drug design.
• ACE has distinct N- and C-domains, offering opportunities for domain-specific inhibition.
• Natural peptides, like bradykinin-potentiating peptides (BPPs) from Bothrops jararaca venom, are explored for therapeutic potential.

Purpose of the Study:

• To investigate natural peptide structures from Bothrops jararaca venom as inhibitors of Angiotensin I-converting enzyme (ACE).
• To analyze the molecular interactions and binding specificities of BPPs with human somatic ACE (sACE).
• To evaluate the potential of BPPs for developing stable, domain-selective ACE inhibitors.

Main Methods:

• Molecular modeling, docking, and molecular dynamics simulations were employed.
• Analysis focused on conserved residues in key binding positions (S2', S1', S1) of the enzyme.
• Investigated electrostatic interactions influencing inhibitor binding and stability.

Main Results:

• BPP9a was identified as the only specific inhibitor for human somatic ACE (sACE).
• Instability of BPP9a in the N-sACE complex was linked to repulsive electrostatic interactions.
• Specific inhibition of the C-terminal domain of sACE was confirmed via interaction with Asp 1008.

Conclusions:

• Peptide-like BPP structures from snake venom are promising candidates for domain-selective ACE inhibitors.
• These natural peptides exhibit potential for high stability and improved pharmacological profiles.
• Further development of BPP-based inhibitors could lead to novel treatments for ACE-related diseases.